CONCENTRATIONS

Financial instruments and related items, which
potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables.
The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may
be in excess of the FDIC insurance limit.

The Company’s revenues earned from sale
of products and services for the year ended December 31, 2018 included 13%, 18%, 22% and 20% (aggregate of 73%) from four customers
of the Company’s total revenues.

The Company’s revenues earned from sale
of products and services for the year ended December 31, 2017 included 12%, 12%, 31%, 12% and 13% (aggregate of 80%) from five
customers of the Company’s total revenues.

Three customers accounted for 44%, 17% and
32% (aggregate of 93%) of the Company’s total accounts receivable at December 31, 2018 and three customers accounted for
12%, 19% and 13% (aggregate of 44%) of the Company’s total accounts receivable at December 31, 2017.

The Company relies on Trinity Rx as its sole
supplier of its Naltrexone implant.

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.